Rhabdomyosarcoma staging: Difference between revisions
Jump to navigation
Jump to search
Line 82: | Line 82: | ||
* Metastases: Present distant metastases | * Metastases: Present distant metastases | ||
|} | |} | ||
h | |||
==References== | ==References== |
Revision as of 16:50, 1 February 2019
Rhabdomyosarcoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Rhabdomyosarcoma staging On the Web |
American Roentgen Ray Society Images of Rhabdomyosarcoma staging |
Risk calculators and risk factors for Rhabdomyosarcoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
According to the Children's Oncology Group, there are four stages of rhabdomyosarcoma based on the location of tumor, size of tumor, involvement of lymph nodes, and metastasis.
Staging of rhabdomyosarcoma
- There are two staging classification for rhabdomyosarcoma:[1]
- Clinical group (CG)
- Created by intergroup rhabdomyosarcoma study group (IRSG) in 1972
- Based on spread of tumor cells at diagnosis and remaining disease after surgery
- Categorized in four groups
- Tumor, node, metastasis system (TNM)
- Based on tumor size, node involvement, and metastases
- Categorized in four groups
- Clinical group (CG)
Stage | Description |
---|---|
I |
|
II |
|
III |
|
IV |
|
Stage | Description |
---|---|
1 |
|
2 |
|
3 |
|
4 |
|
h
References
- ↑ Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B; et al. (1990). "Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee". J Clin Oncol. 8 (3): 443–52. doi:10.1200/JCO.1990.8.3.443. PMID 2407808.
- ↑ Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C; et al. (1995). "The Third Intergroup Rhabdomyosarcoma Study". J Clin Oncol. 13 (3): 610–30. doi:10.1200/JCO.1995.13.3.610. PMID 7884423.
- ↑ Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB; et al. (2001). "Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease". J Clin Oncol. 19 (12): 3091–102. doi:10.1200/JCO.2001.19.12.3091. PMID 11408506.